Preoperative monocyte-to-lymphocyte ratio as a potential predictor of bladder cancer.
inflammation biomarkers
monocyte
monocyte-to-lymphocyte ratio
non muscle invasive bladder cancer
Journal
Journal of basic and clinical physiology and pharmacology
ISSN: 2191-0286
Titre abrégé: J Basic Clin Physiol Pharmacol
Pays: Germany
ID NLM: 9101750
Informations de publication
Date de publication:
01 Nov 2022
01 Nov 2022
Historique:
received:
08
07
2022
accepted:
28
07
2022
pubmed:
20
8
2022
medline:
18
11
2022
entrez:
19
8
2022
Statut:
epublish
Résumé
The aim of this study was to investigate the role of preoperative Monocyte-to-Lymphocyte ratio (MLR) as a potential predictor of bladder cancer (BC). Clinical data of patients who underwent TURBT at our institution between 2017 and 2021 were collected and retrospectively analysed. MLR was obtained from preoperative blood analyses performed within 1 month from hospital admission. The association of MLR with different clinic-pathological features obtained from histological reports was further analysed. Statistical analysis was performed using the Kruskal Wallis test for non-parametric variables, assuming p<0.05 as statistically significant. 510 patients were included in the study (81% males, 19% females), with a mean age of 71.66 ± 11.64 years. Mean MLR was higher in patients with any-type bladder cancer, reporting an MLR of 0.41 ± 0.11 compared to 0.38 ± 0.43 in patients without bladder cancer (p=0.043). In the subsequent comparison among low-grade and high-grade bladder cancer, MLR did not report statistically significant differences, with 0.29 ± 0.12 for low-grade BC and 0.51 ± 0.81 for high-grade BC (p=0.085). Our findings reported elevated preoperative MLR should be considered a potential biomarker predicting malignancy for bladder tumours. Furthermore, research are necessary to assess its role in discerning low-grade from high-grade patients.
Identifiants
pubmed: 35985034
pii: jbcpp-2022-0179
doi: 10.1515/jbcpp-2022-0179
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
751-757Informations de copyright
© 2022 the author(s), published by De Gruyter, Berlin/Boston.
Références
Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. https://doi.org/10.3322/caac.21492.
Ferlay, J, Colombet, M, Soerjomataram, I, Parkin, DM, Piñeros, M, Znaor, A, et al.. Cancer statistics for the year 2020: an overview. Int J Cancer 2021;149:778–89. https://doi.org/10.1002/ijc.33588.
Saginala, K, Barsouk, A, Aluru, JS, Rawla, P, Padala, SA, Barsouk, A. Epidemiology of bladder cancer. Med Sci 2020;8:E15. https://doi.org/10.3390/medsci8010015.
Klaile, Y, Schlack, K, Boegemann, M, Steinestel, J, Schrader, AJ, Krabbe, LM. Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease? Transl Androl Urol 2016;5:692–701. https://doi.org/10.21037/tau.2016.06.13.
Zhu, S, Yu, W, Yang, X, Wu, C, Cheng, F. Traditional classification and novel subtyping systems for bladder cancer. Front Oncol 2020;10:102. https://doi.org/10.3389/fonc.2020.00102.
Tarantino, G, Crocetto, F, Di Vito, C, Creta, M, Martino, R, Pandolfo, SD, et al.. Association of nafld and insulin resistance with non metastatic bladder cancer patients: a cross-sectional retrospective study. J Clin Med 2021;10:346. https://doi.org/10.3390/jcm10020346.
Babjuk, M, Burger, M, Capoun, O, Cohen, D, Compérat, EM, Dominguez Escrig, JL, et al.. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2022;81:75–94. https://doi.org/10.1016/j.eururo.2021.08.010.
Gupta, SC, Kim, JH, Prasad, S, Aggarwal, BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010;29:405–34. https://doi.org/10.1007/s10555-010-9235-2.
Fankhauser, CD, Sander, S, Roth, L, Gross, O, Eberli, D, Sulser, T, et al.. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy. Br J Cancer 2018;118:825–30. https://doi.org/10.1038/bjc.2017.467.
Li, YX, Chang, JY, He, MY, Wang, HR, Luo, DQ, Li, FH, et al.. Neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) predict clinical outcome in patients with stage IIB cervical cancer. J Oncol 2021;2021:2939162. https://doi.org/10.1155/2021/2939162.
Lijuan, W, Yuting, Z, Chaoyang, L, Ju, Y. Neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios may not be useful markers to assess disease activity in rheumatoid arthritis: a STROBE-compliant article. Medicine 2021;100:e27631, https://doi.org/10.1097/md.0000000000027631.
Song, H, Jeong, MJ, Cha, J, Lee, JS, Yoo, JG, Song, MJ, et al.. Preoperative neutrophil-to-lymphocyte, platelet-to-lymphocyte and monocyte-to-lymphocyte ratio as a prognostic factor in non-endometrioid endometrial cancer. Int J Med Sci 2021;18:3712–7. https://doi.org/10.7150/ijms.64658.
Urbanowicz, T, Michalak, M, Olasińska-Wiśniewska, A, Rodzki, M, Witkowska, A, Gąsecka, A, et al.. Neutrophil counts, neutrophil-to-lymphocyte ratio, and systemic inflammatory response index (SIRI) predict mortality after off-pump coronary artery bypass surgery. Cells 2022;11:1124. https://doi.org/10.3390/cells11071124.
Ferro, M, Caputo, VF, Barone, B, Imbimbo, C, de Cobelli, O, Crocetto, F. Lymphocyte to monocyte ratio: a new independent prognostic factor in bladder cancer progression? Front Oncol 2021;11:754649. https://doi.org/10.3389/fonc.2021.754649.
Ferro, M, Babă, DF, de Cobelli, O, Musi, G, Lucarelli, G, Terracciano, D, et al.. Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. Future Sci OA 2021;7:FSO709. https://doi.org/10.2144/fsoa-2021-0008.
Mayeux, R. Biomarkers: potential uses and limitations. NeuroRx 2004;1:182–8. https://doi.org/10.1602/neurorx.1.2.182.
Jain, KK. Role of biomarkers in health care. In: Jain, KK, curatore, editors. The Handbook of Biomarkers [Internet]. Totowa, NJ: Humana Press; 2010:115–88 pp. [citato 26 giugno 2022].
Wang, DQ, Shuai, J, Zheng, H, Guo, ZQ, Huang, Q, Xu, XF, et al.. Can routine blood and urine parameters reveal clues to detect bladder cancer? A case-control study. Front Oncol 2021;11:796975. https://doi.org/10.3389/fonc.2021.796975.
Roxburgh, CSD, McMillan, DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 2014;110:1409–12. https://doi.org/10.1038/bjc.2014.90.
Colotta, F, Allavena, P, Sica, A, Garlanda, C, Mantovani, A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073–81. https://doi.org/10.1093/carcin/bgp127.
Greten, FR, Grivennikov, SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019;51:27–41. https://doi.org/10.1016/j.immuni.2019.06.025.
Zhao, H, Wu, L, Yan, G, Chen, Y, Zhou, M, Wu, Y, et al.. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021;6:1–46. https://doi.org/10.1038/s41392-021-00658-5.
Parihar, A, Eubank, TD, Doseff, AI. Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J Innate Immun 2010;2:204–15. https://doi.org/10.1159/000296507.
Richards, DM, Hettinger, J, Feuerer, M. Monocytes and macrophages in cancer: development and functions. Cancer Microenviron 2013;6:179–91. https://doi.org/10.1007/s12307-012-0123-x.
Riabov, V, Gudima, A, Wang, N, Mickley, A, Orekhov, A, Kzhyshkowska, J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014;5:75. https://doi.org/10.3389/fphys.2014.00075.
Zhu, X, Wu, SQ, Xu, R, Wang, YH, Zhong, ZH, Zhang, L, et al.. The evaluation of monocyte lymphocyte ratio as a preoperative predictor in urothelial malignancies: a pooled analysis based on comparative studies. Sci Rep 2019;9:6280. https://doi.org/10.1038/s41598-019-42781-y.
Shi, H, Wang, K, Yuan, J, Mao, W, Wu, Z, Liu, Q, et al.. A high monocyte-to-lymphocyte ratio predicts poor prognosis in patients with radical cystectomy for bladder cancer. Transl Cancer Res 2020;9:5255–67. https://doi.org/10.21037/tcr-20-1060.
Luo, Y, Shi, X, Li, W, Mo, L, Yang, Z, Li, X, et al.. Evaluation of the clinical value of hematological parameters in patients with urothelial carcinoma of the bladder. Medicine 2018;97:e0351. https://doi.org/10.1097/md.0000000000010351.
Wang, Q, Huang, T, Ji, J, Wang, H, Guo, C, Sun, X, et al.. Prognostic utility of the combination of pretreatment monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NMIBC after transurethral resection. Biomark Med 2019;13:1543–55. https://doi.org/10.2217/bmm-2019-0398.
Shi, L, Qin, X, Wang, H, Xia, Y, Li, Y, Chen, X, et al.. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget 2017;8:18792–801. https://doi.org/10.18632/oncotarget.13320.
Xiang, J, Zhou, L, Li, X, Bao, W, Chen, T, Xi, X, et al.. Preoperative monocyte-to-lymphocyte ratio in peripheral blood predicts stages, metastasis, and histological grades in patients with ovarian cancer. Transl Oncol 2017;10:33–9. https://doi.org/10.1016/j.tranon.2016.10.006.
De Giorgi, U, Mego, M, Scarpi, E, Giuliano, M, Giordano, A, Reuben, JM, et al.. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 2012;12:264–9. https://doi.org/10.1016/j.clbc.2012.04.004.
Joseph, N, Dovedi, SJ, Thompson, C, Lyons, J, Kennedy, J, Elliott, T, et al.. Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. Ann Oncol 2016;27:294–9. https://doi.org/10.1093/annonc/mdv546.
Fini, MA, Elias, A, Johnson, RJ, Wright, RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med 2012;1:16. https://doi.org/10.1186/2001-1326-1-16.
Mi, S, Gong, L, Sui, Z. Friend or foe? An unrecognized role of uric acid in cancer development and the potential anticancer effects of uric acid-lowering drugs. J Cancer 2020;11:5236–44. https://doi.org/10.7150/jca.46200.
Wang, W, Xu, D, Wang, B, Yan, S, Wang, X, Yin, Y, et al.. Increased risk of cancer in relation to gout: a review of three prospective cohort studies with 50, 358 subjects. Mediators Inflamm 2015;2015:680853. https://doi.org/10.1155/2015/680853.
Jiang, M, Ren, L, Chen, S, Li, G. Serum uric acid levels and risk of eight site-specific cancers: a mendelian randomization study. Front Genet 2021;12:608311. https://doi.org/10.3389/fgene.2021.608311.
Ahechu, P, Zozaya, G, Martí, P, Hernández-Lizoáin, JL, Baixauli, J, Unamuno, X, et al.. NLRP3 inflammasome: a possible link between obesity-associated low-grade chronic inflammation and colorectal cancer development. Front Immunol 2018;9:2918. https://doi.org/10.3389/fimmu.2018.02918.
Ames, BN, Cathcart, R, Schwiers, E, Hochstein, P. Uric acid provides an antioxidant defense in humans against oxidant – and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858–62. https://doi.org/10.1073/pnas.78.11.6858.
Chen, CJ, Yen, JH, Chang, SJ. Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol 2014;43:385–90. https://doi.org/10.3109/03009742.2013.878387.
Tanaka, T, Narazaki, M, Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014;6:a016295. https://doi.org/10.1101/cshperspect.a016295.
Shen, C, Zhou, K, Wang, W, Zhang, Y, Liu, X. The prognostic value of preoperative serum albumin in patients with bladder urothelial carcinoma undergoing transurethral resection of bladder tumor: a prospective cohort study. Medicine 2021;100:e26548. https://doi.org/10.1097/md.0000000000026548.